Lim CN, Mo G, Bhardwaj R, Comisar CM, et al. A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged >/=6 to <12 years) with a history of migraine. Headache 2025 Oct 24. doi: 10.1111/head.15074.
PMID: 41133671